Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
- PMID: 26184483
- DOI: 10.1158/1535-7163.MCT-14-0636
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Abstract
Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently, it is important to understand the molecular mechanisms underlying the appearance of this phenomenon to find ways of circumventing it and to improve and optimize treatments. This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptotic), and epigenetic mechanisms.
©2015 American Association for Cancer Research.
Similar articles
-
Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.J Cell Physiol. 2018 Mar;233(3):2193-2201. doi: 10.1002/jcp.25966. Epub 2017 May 23. J Cell Physiol. 2018. PMID: 28422287 Review.
-
Oxaliplatin: mechanism of action and antineoplastic activity.Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12. Semin Oncol. 1998. PMID: 9609103 Review.
-
Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.Curr Cancer Drug Targets. 2003 Feb;3(1):21-9. doi: 10.2174/1568009033333727. Curr Cancer Drug Targets. 2003. PMID: 12570658 Review.
-
Cellular and molecular pharmacology of oxaliplatin.Mol Cancer Ther. 2002 Jan;1(3):227-35. Mol Cancer Ther. 2002. PMID: 12467217 Review.
-
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.Cancer Res. 1998 Aug 15;58(16):3579-85. Cancer Res. 1998. PMID: 9721864
Cited by
-
Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance.Int J Mol Sci. 2019 Aug 30;20(17):4242. doi: 10.3390/ijms20174242. Int J Mol Sci. 2019. PMID: 31480221 Free PMC article. Review.
-
Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer.RSC Adv. 2019 Oct 2;9(54):31413-31424. doi: 10.1039/c9ra06146k. eCollection 2019 Oct 1. RSC Adv. 2019. PMID: 35527927 Free PMC article.
-
Long Noncoding RNA (lncRNA)-Mediated Competing Endogenous RNA Networks Provide Novel Potential Biomarkers and Therapeutic Targets for Colorectal Cancer.Int J Mol Sci. 2019 Nov 16;20(22):5758. doi: 10.3390/ijms20225758. Int J Mol Sci. 2019. PMID: 31744051 Free PMC article. Review.
-
Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition.J Enzyme Inhib Med Chem. 2022 Dec;37(1):236-251. doi: 10.1080/14756366.2021.2001805. J Enzyme Inhib Med Chem. 2022. PMID: 34894961 Free PMC article.
-
The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231206003. doi: 10.1177/15330338231206003. Technol Cancer Res Treat. 2023. PMID: 37849311 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
